caa a22 4500 605490287 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0692-4 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0692-4 Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience [Elektronische Daten] [Keishi Makino, Hideo Nakamura, Taku-ichiro Hide, Jun-ichiro Kuroda, Shigetoshi Yano, Jun-ichi Kuratsu] Abstract : Background: This retrospective single-center study assessed the feasibility, outcomes, and side-effects of high-dose methotrexate (HD-MTX) plus procarbazine in the treatment of immunocompetent patients with primary central nervous system lymphoma (PCNSL). Methods: Ninety-one patients diagnosed with PCNSL between January 2001 and December 2011 were treated with HD-MTX plus procarbazine. To reduce neurotoxicity in patients aged ≥60years, only those not responding to chemotherapy and patients with relapse underwent whole-brain irradiation. Results: All 91 consecutive patients were scheduled to receive HD-MTX. Their median age was 66years (range 32-88years) and their median Karnofsky performance score was 40 (range 20-100). While 56 patients (61.5%) completed 3 cycles of HD-MTX chemotherapy and 48 (52.7%) showed a complete response, treatment was stopped in 11 patients (12.1%) due to toxicity. The median overall survival and progression-free survival were 40.6 and 11.7months, respectively. Overall survival was significantly improved in patients who completed 3 cycles of chemotherapy compared with those did not (56.4 vs 24.0months; p=0.013 by univariate and p=0.022 by multivariate analysis). Conclusions: Initial treatment with HD-MTX plus procarbazine was effective in patients with PCNSL. Completion of 3 cycles of HD-MTX chemotherapy was a significant independent prognostic factor for patient survival. Japan Society of Clinical Oncology, 2014 Primary central nervous system lymphoma nationallicence High-dose methotrexate nationallicence Chemotherapy nationallicence Retrospective study nationallicence Prognostic impact nationallicence Makino Keishi Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut Nakamura Hideo Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut Hide Taku-ichiro Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut Kuroda Jun-ichiro Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut Yano Shigetoshi Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut Kuratsu Jun-ichi Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 29-34 1341-9625 20:1<29 2015 20 10147 https://doi.org/10.1007/s10147-014-0692-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0692-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Makino Keishi Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 700 1- Nakamura Hideo Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 700 1- Hide Taku-ichiro Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 700 1- Kuroda Jun-ichiro Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 700 1- Yano Shigetoshi Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 700 1- Kuratsu Jun-ichi Department of Neurosurgery, Faculty of Medicine, Kumamoto University, 1-1-1 Honjo Chuo-ku, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 29-34 1341-9625 20:1<29 2015 20 10147